​Eli Lilly and Company (LLY): Among the Best Stocks to Buy While the Market Is Down

Why It Matters

The acquisition diversifies Lilly’s revenue base and accelerates entry into high‑growth oncology, mitigating reliance on weight‑loss drugs and enhancing long‑term shareholder value.

Key Takeaways

• Lilly to acquire Kelonia for up to $7 billion
• Deal adds in‑body CAR‑T platform targeting multiple myeloma
• Upfront cash $3.25 billion, milestones up to $3.75 billion
• Oncology market projected $409 billion by 2028
• 83% of analysts maintain Buy rating, 38% upside target

Pulse Analysis

Eli Lilly’s move to purchase Kelonia Therapeutics reflects a broader industry trend of big pharma bolstering oncology pipelines amid waning growth from legacy products. While the company’s tirzepatide‑driven weight‑loss segment has delivered double‑digit revenue gains, competitive pressures and pricing scrutiny have prompted executives to seek high‑margin, innovative therapies. By securing an in‑body CAR‑T technology that eliminates ex‑vivo cell manipulation, Lilly not only gains a differentiated asset but also shortens development timelines, a critical advantage in the fast‑moving cancer market.

Kelonia’s lead candidate, KLN‑1010, targets BCMA in relapsed or refractory multiple myeloma—a segment where existing CAR‑T therapies have shown efficacy but are hampered by complex manufacturing and toxic conditioning regimens. The iGPS particle platform administers gene‑editing vectors directly into patients, potentially reducing costs and expanding access. With the global oncology market expected to surpass $409 billion by 2028, the acquisition positions Lilly to capture a slice of this growth, especially as investors increasingly favor companies with diversified, pipeline‑rich portfolios.

Analyst sentiment underscores the strategic merit of the deal: 83% of the 35 covering analysts retain a Buy rating, and the consensus 12‑month price target suggests more than 38% upside from current levels. For investors, the transaction offers a dual‑play—leveraging Lilly’s cash‑rich balance sheet to fund a high‑potential oncology venture while mitigating concentration risk tied to weight‑loss drugs. As market volatility persists, stocks that combine solid cash flow with pipeline diversification, like Lilly, become attractive candidates for long‑term portfolios.